Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study)

Möller, Christian; Dreborg, Sten; Ferdousi, Hosne Ara; Halken, Susanne; Høst, Arne; Jacobsen, Lars; Koivikko, A.; Koller, D. Y.; Niggemann, B.; Norberg, Lene Annette; Urbanek, R.; Valovirta, Erkka; Wahn, Ulrich

doi:10.1067/mai.2002.121317

Cited by 957 publications

(647 citation statements)

References 29 publications

Supporting

Mentioning

564

Contrasting

Unclassified

Order By: Relevance

“…26,27 Furthermore, a preventive effect of specific immunotherapy on the natural history of allergic disease may be lost with later onset of therapy. 28,29 We did not set out to evaluate the safety of SLIT in young children, but evaluated young Italian children who received SLIT as part of the management of their asthma or rhinoconjunctivitis irrespective of the reason why SLIT had been prescribed. This particular formulation has been proven effective in children.…”

Section: Discussionmentioning

confidence: 99%

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

Fiocchi¹,

Pajno

Grutta³

et al. 2005

Annals of Allergy, Asthma & Immunology

113

View full text Add to dashboard Cite

Background:The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly established, and position papers discourage its use in children younger than 5 years.Objective: To assess the safety of high-dose sublingual-swallow immunotherapy (SLIT) in a group of children younger than 5 years.Methods: Sixty-five children (51 boys and 14 girls; age range, 38 -80 months; mean Ϯ SD age, 60 Ϯ 10 years; median age, 60 months) were included in this observational study. They were treated with SLIT with a build-up phase of 11 days, culminating in a top dose of 300 IR (index of reactivity) and a maintenance phase of 300 IR 3 times a week. The allergens used were house dust mites in 42 patients, grass pollen in 11 patients, olive pollen in 5 patients, Parietaria pollen in 4 patients, and cypress pollen in 3 patients. All adverse reactions and changes in the treatment schedule were compared in 2 subgroups: children 38 to 60 months old and children 61 to 80 months old.Results: The average cumulative dose of SLIT was 36,900 IR. Adverse reactions were observed in 11 children, none of them severe enough to require discontinuation of immunotherapy. Six reactions occurred in the 60 months or younger age group and 7 in the older than 60 months age group, with no differences between these 2 groups.Conclusion: High-dose immunotherapy in children younger than 5 years does not cause more adverse reactions than in children aged 5 to 7 years. There is no reason to forbear studies on safety and efficacy of these preparations in young children.Ann Allergy Asthma Immunol. 2005;95:254-258.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

Fiocchi¹,

Pajno

Grutta³

et al. 2005

Annals of Allergy, Asthma & Immunology

113

View full text Add to dashboard Cite

show abstract

“…The PAT Study has considered 205 children (6 to 14 years old) suffering from allergic rhinitis without asthma at inclusion. 30 After three years of grass or birch pollen subcutaneous SIT, less children in the treated arm had asthma than in the control group (odd ratio 2.52; p < 0.05). For 147 children an evaluation was also performed seven years after SIT discontinuation.…”

Section: Special Focus Reviewmentioning

confidence: 99%

Specific immunotherapy in grass pollen allergy

Mailhol

Didier²

2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…The presence of concomitant AR is often associated with the difficulty of asthma control 19. In fact, here, we showed that AR increased the risk of asthma attacks and emergency room visit (Fig.…”

Section: Treatment Strategy Of Asthma With Comorbid Ar or Japanese Cementioning

confidence: 53%

Asthma in Patients With Japanese Cedar Pollinosis

Tanaka¹,

Minoguchi²,

Pawankar³

et al. 2012

World Allergy Organization Journal

View full text Add to dashboard Cite

Abstract:Japanese cedar pollen is the most common causative allergen for seasonal allergic rhinitis (AR) in Japan. More commonly known as Japanese cedar pollinosis, it occurs in spring causing the typical symptoms of seasonal AR, such as sneezing, rhinorrhea, nasal obstruction, nasal itching, and itching of the eyes. Previous reports indicate that the prevalence of Japanese cedar pollinosis among Japanese was 26.5%. According to a more recent questionnaire-based survey, the prevalence of Japanese cedar pollinosis in patients with adult asthma might be up to 30% to 50%, suggesting higher rates than that previously reported. Moreover, 30% to 60% of adult asthmatic patients with concomitant pollinosis have exacerbations of their asthma symptoms during the Japanese cedar pollen season. These findings suggest that concomitant Japanese cedar pollinosis may be an aggravating factor in patients with asthma. As with other pollens, such as grass and birch, Japanese cedar pollen was shown to be a trigger factor for worsening asthma. In clinical practice, a number of Japanese patients with asthma are monosensitized to Japanese cedar pollen but not to other antigens. Further studies are needed to elucidate the mechanisms of Japanese cedar pollen in inducing and in exacerbating asthma. The presence of concomitant AR is often associated with the difficulty in asthma control. However, there has been a controversy whether treating concomitant AR by intranasal corticosteroid would produce better asthma-related outcomes in patients with asthma and AR. The effect of treating concomitant cedar pollinosis by intranasal corticosteroids on asthma control in patients with asthma and cedar pollinosis also remains unknown. Certain systemic treatments, such as leukotriene receptor antagonist and anti-IgE monoclonal antibody, are supposed to reduce the symptoms of both asthma and AR in patients with asthma and concomitant AR. In conclusion, Japanese cedar pollinosis is often associated with exacerbations of asthma. Further investigations are expected to elucidate the precise impact and mechanisms of Japanese cedar pollinosis in asthma.

show abstract

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study)

Cited by 957 publications

References 29 publications

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

Specific immunotherapy in grass pollen allergy

Asthma in Patients With Japanese Cedar Pollinosis

Contact Info

Product

Resources

About